Biolargo, Inc. financial data

Symbol
BLGO on OTC
Industry
Chemicals & Allied Products
Location
14921 Chestnut St., Westminster, CA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
NUWAY MEDICAL INC (to 4/3/2007), NUWAY ENERGY INC (to 2/5/2003), LATIN AMERICAN CASINOS INC (to 2/15/2001)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 233 % -13.8%
Quick Ratio 6.46 % -42.7%
Debt-to-equity 55.5 % +20.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 301M shares +4.36%
Common Stock, Shares, Outstanding 293M shares +5.2%
Entity Public Float 40.9M USD +0.38%
Common Stock, Value, Issued 200K USD +4.17%
Weighted Average Number of Shares Outstanding, Basic 296M shares +4.03%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 2.54M USD +47.2%
Operating Income (Loss) -4.2M USD +4.51%
Earnings Per Share, Basic -0.01 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.77M USD +33.3%
Accounts Receivable, after Allowance for Credit Loss, Current 2.1M USD +103%
Inventory, Net 176K USD +38.6%
Assets, Current 7.11M USD +46.7%
Property, Plant and Equipment, Net 1.81M USD +234%
Operating Lease, Right-of-Use Asset 1.04M USD +29.4%
Other Assets, Noncurrent 70K USD +1.45%
Assets 10.1M USD +50.5%
Accounts Payable, Current 1.47M USD +206%
Employee-related Liabilities, Current 29K USD -86.4%
Contract with Customer, Liability, Current 85K USD +750%
Liabilities, Current 3.01M USD +133%
Operating Lease, Liability, Noncurrent 965K USD +33.8%
Liabilities 4.16M USD +62.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -242K USD -49.4%
Retained Earnings (Accumulated Deficit) -148M USD -1.92%
Stockholders' Equity Attributable to Parent 6M USD -18.5%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 5.89M USD +42.9%
Liabilities and Equity 10.1M USD +50.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 481K USD
Net Cash Provided by (Used in) Financing Activities 1.08M USD -28.3%
Net Cash Provided by (Used in) Investing Activities -863K USD -1698%
Common Stock, Shares Authorized 550M shares 0%
Common Stock, Shares, Issued 298M shares +3.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 797K USD -43.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 12K USD -20%
Deferred Tax Assets, Valuation Allowance 22.3M USD +4.42%
Operating Lease, Liability 1.07M USD +30.8%
Depreciation 38K USD +46.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -2.86M USD +10.7%
Lessee, Operating Lease, Liability, to be Paid 1.91M USD +6.3%
Operating Lease, Liability, Current 105K USD +8.25%
Lessee, Operating Lease, Liability, to be Paid, Year Two 289K USD +29%
Lessee, Operating Lease, Liability, to be Paid, Year One 282K USD +4.83%
Operating Lease, Weighted Average Discount Rate, Percent 0.18 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 933K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 296K USD +88.5%
Deferred Tax Assets, Operating Loss Carryforwards 22.3M USD +4.42%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 245K USD +53.1%
Additional Paid in Capital 154M USD +0.97%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 338K USD -21.4%
Interest Expense 45K USD -47.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%